Suppr超能文献

尼日利亚耐多药结核病的患病率:一项系统评价与荟萃分析。

Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis.

作者信息

Onyedum Cajetan C, Alobu Isaac, Ukwaja Kingsley Nnanna

机构信息

Department of Medicine, College of Medicine, University of Nigeria, Enugu Campus, Enugu, Nigeria.

National Tuberculosis and Leprosy Control Programme, Ministry of Health, Abakaliki, Ebonyi State, Nigeria.

出版信息

PLoS One. 2017 Jul 13;12(7):e0180996. doi: 10.1371/journal.pone.0180996. eCollection 2017.

Abstract

BACKGROUND

Drug-resistant tuberculosis (TB) undermines control efforts and its burden is poorly understood in resource-limited settings. We performed a systematic review and meta-analysis to provide an up-to-date summary of the extent of drug-resistant TB in Nigeria.

METHODS

We searched PubMed, Scopus, Embase, HINARI, AJOL, the Cochrane library, Web of Science, and Google Scholar for reports published before January 31 2017, that included any resistance, mono-resistance or multidrug resistance to anti-TB drugs in Nigeria. Summary estimates were calculated using random effects models.

RESULTS

We identified 34 anti-TB drug resistance surveys with 8002 adult TB patients consisting of 2982 new and 5020 previously-treated cases. The prevalence rate of any drug resistance among new TB cases was 32.0% (95% CI 24.0-40.0%; 734/2892) and among previously-treated cases, the rate was 53.0% (95% CI 35.0-71.0%; 1467/5020). Furthermore, multidrug resistance among new and previously-treated cases was 6.0% (95% CI 4.0-8.0%;161/2502)and 32.0% (95%CI 20.0-44.0; 357/949), respectively. There was significant heterogeneity between the studies (p<0.001, I2 tests). The prevalence of drug-resistant TB varied according to methods of drug susceptibility testing and geographic region of Nigeria.

CONCLUSION

The burden of drug-resistant TB in Nigeria is high. We recommend that a national anti-TB drug resistance survey be carried out, and strategies for case detection and programmatic management of drug-resistant TB in Nigeria need to be strengthened.

摘要

背景

耐多药结核病破坏了防控工作,在资源有限的环境中,其负担情况鲜为人知。我们进行了一项系统综述和荟萃分析,以提供尼日利亚耐多药结核病程度的最新总结。

方法

我们检索了PubMed、Scopus、Embase、HINARI、AJOL、Cochrane图书馆、科学网和谷歌学术,查找2017年1月31日前发表的报告,这些报告包括尼日利亚抗结核药物的任何耐药性、单耐药或多耐药情况。使用随机效应模型计算汇总估计值。

结果

我们确定了34项抗结核药物耐药性调查,涉及8002例成年结核病患者,其中包括2982例新发病例和5020例既往治疗病例。新发病例中任何药物耐药的患病率为32.0%(95%可信区间24.0 - 40.0%;734/2892),既往治疗病例中的患病率为53.0%(95%可信区间35.0 - 71.0%;1467/5020)。此外,新发病例和既往治疗病例中的多药耐药率分别为6.0%(95%可信区间4.0 - 8.0%;161/2502)和32.0%(95%可信区间20.0 - 44.0%;357/949)。研究之间存在显著异质性(p<0.001,I²检验)。耐多药结核病的患病率因药物敏感性检测方法和尼日利亚的地理区域而异。

结论

尼日利亚耐多药结核病的负担很高。我们建议开展全国性抗结核药物耐药性调查,并加强尼日利亚耐药结核病病例检测和规划管理的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8234/5509256/95fba18677e7/pone.0180996.g001.jpg

相似文献

1
Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis.
PLoS One. 2017 Jul 13;12(7):e0180996. doi: 10.1371/journal.pone.0180996. eCollection 2017.
4
Prevalence of drug-resistant pulmonary tuberculosis in India: systematic review and meta-analysis.
BMC Public Health. 2017 Oct 17;17(1):817. doi: 10.1186/s12889-017-4779-5.
5
Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.
Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2.
6
Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
Cochrane Database Syst Rev. 2022 May 18;5(5):CD014841. doi: 10.1002/14651858.CD014841.pub2.
7
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

引用本文的文献

4
Molecular detection of rifampicin-resistant by polymerase chain reaction in Ethiopia: a systematic review and meta-analysis.
Front Med (Lausanne). 2024 Jun 7;11:1319845. doi: 10.3389/fmed.2024.1319845. eCollection 2024.
5
Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control.
Front Public Health. 2024 May 16;12:1374703. doi: 10.3389/fpubh.2024.1374703. eCollection 2024.
6
Role of the IL8 rs4073 polymorphism in central nervous system toxicity in patients receiving multidrug-resistant tuberculosis treatment.
J Bras Pneumol. 2024 Feb 12;50(1):e20230338. doi: 10.36416/1806-3756/e20230338. eCollection 2024.
7
8
Mycobacterium tuberculosis complex drug-resistance, phylogenetics, and evolution in Nigeria: Comparison with Ghana and Cameroon.
PLoS Negl Trop Dis. 2023 Oct 12;17(10):e0011619. doi: 10.1371/journal.pntd.0011619. eCollection 2023 Oct.
9
Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis.
Infect Dis Poverty. 2023 May 25;12(1):57. doi: 10.1186/s40249-023-01107-x.

本文引用的文献

1
Anti-tuberculosis drug resistance in Ethiopia: systematic review.
Int J Tuberc Lung Dis. 2017 Jan 1;21(1):18-22. doi: 10.5588/ijtld.16.0286.
3
The Prevalence of Drug-Resistant Tuberculosis in Mainland China: An Updated Systematic Review and Meta-Analysis.
PLoS One. 2016 Feb 9;11(2):e0148041. doi: 10.1371/journal.pone.0148041. eCollection 2016.
4
Multidrug resistance and demography of newly diagnosed tuberculosis patients in Cross River State, Nigeria.
Int J Mycobacteriol. 2013 Jun;2(2):89-93. doi: 10.1016/j.ijmyco.2013.03.002. Epub 2013 Apr 22.
7
Metaprop: a Stata command to perform meta-analysis of binomial data.
Arch Public Health. 2014 Nov 10;72(1):39. doi: 10.1186/2049-3258-72-39. eCollection 2014.
8
Risk factors of treatment default and death among tuberculosis patients in a resource-limited setting.
Asian Pac J Trop Med. 2014 Dec;7(12):977-84. doi: 10.1016/S1995-7645(14)60172-3.
9
Prevalence of drug-resistant tuberculosis in Iran: systematic review and meta-analysis.
Am J Infect Control. 2014 Nov;42(11):1212-8. doi: 10.1016/j.ajic.2014.07.017. Epub 2014 Sep 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验